)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Tourmaline Bio (TRML) investor relations material
Tourmaline Bio Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Achieved positive topline Phase 2 TRANQUILITY trial results for pacibekitug, showing significant and durable hs-CRP reduction and favorable safety profile in cardiovascular inflammation.
Focused on pacibekitug development for immune and inflammatory diseases, with lead indications in cardiovascular inflammation and thyroid eye disease.
Planning Phase 3 cardiovascular outcomes trial and Phase 2 proof-of-concept trial in abdominal aortic aneurysm, both advancing in H2 2025.
Ongoing pivotal Phase 2b spiriTED trial in thyroid eye disease, with topline data expected in early 2026.
Accumulated deficit reached $181.3 million as of June 30, 2025; expects continued losses as R&D activities expand.
Financial highlights
Net loss of $23.1 million for Q2 2025, compared to $17.5 million in Q2 2024; net loss per share was $0.90 for Q2 2025.
Operating expenses rose to $26.0 million in Q2 2025 from $22.0 million in Q2 2024, driven by higher R&D and payroll costs.
Cash, cash equivalents, and investments totaled $256.4 million as of June 30, 2025.
Net cash used in operating activities was $41.9 million for the first half of 2025, up from $32.9 million in the prior year period.
No revenue generated; company remains pre-commercial.
Outlook and guidance
Cash position expected to fund operations into the second half of 2027 based on current operating plan.
Expects continued increase in R&D and G&A expenses as clinical programs advance and headcount grows.
Additional TRANQUILITY trial data to be presented at the European Society of Cardiology Congress in August 2025.
Plans to finance future needs through equity/debt offerings, collaborations, or licensing arrangements.
Phase 2 proof-of-concept trial in abdominal aortic aneurysm set to begin in H2 2025.
Discuss plans for pacibekitug's TED development.
Elaborate on Phase 3 ASCVD trial planning progress.
Explain the increase in R&D expenses.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Tourmaline Bio earnings date
Q3 20256 Nov, 2025
Next Tourmaline Bio earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Tourmaline Bio Inc. is a biotechnology company focused on developing treatments for immune and inflammatory diseases. The company is engaged in the late-stage clinical development of therapies aimed at significantly improving the lives of patients with severe autoimmune and inflammatory conditions. Its product pipeline includes medicines designed to address conditions such as atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage